Introduction Whilst alpha feto-protein is secreted by some hepatocellular carcinoma, it is not recommended for diagnosis in current guidelines. It is well recognised as a marker of prognosis in hepatocellular carcinoma and therefore we aimed to determine an appropriate cut-off value that would provide optimal prognostic information for this cancer.
Method Consecutive patients (n = 432) with valid alpha feto-protein measurements diagnosed with hepatocellular carcinoma during 2005 to 2014 in the Liverpool region, UK were included. The area under the receiver operating characteristic curve of alpha feto-protein by status of patients was used to determine the optimal cut-off. This value was then used to assess overall survival of the study population by type of treatment. The predictive performance of the new cut-off was assessed by its performance in the Hepatoma arterial-embolisation prognostic score of patients treated by trans-arterial chemoembolisation.
Results Serum alpha feto-protein value, ≥43 ng/mL predicted prognosis (sensitivity 48% / specificity 78%) better than ≥400 ng/mL (sensitivity 28%/specificity 89%). The median survival was 28 months (95% CI: 21–33) in patients with AFP <43 ng/mL and 7 months (95% CI: 5–8) for those whose alpha feto-protein was ≥43 ng/mL. Also, accurate prediction of survival for hepatocellular carcinoma patients receiving loco-regional therapy (34 months vs. 14 months, p < 0.0001) and curative therapy (43 months vs. 15 months, p = 0.001) was obtained.
Conclusion An alpha feto-protein of ≥43 was defined as the optimal cut-off to aid prognostic predictions. These results require external validation before recommendation for decision making in clinical practice.
Disclosure of interest None Declared.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.